Make a donation

Wednesday, February 17, 2021

New Canadian pharmaceutical company brings novel cancer therapies to market

(Toronto, Ont.) January 27, 2021 ¬– FORUS Therapeutics launches today, bringing a new pharmaceutical company onto the Canadian landscape. With a highly-experienced and proven team, an FDA-approved product already in its pipeline, and significant financial investment secured, the Toronto-based company looks to bring innovative cancer therapies to Canadian patients, new treatment tools for caregivers and physicians, and in the future, be a preferred partner for emerging Canadian-based research companies.

FORUS has also secured an exclusive Canadian distribution agreement with Karyopharm Therapeutics Inc. (Nasdaq: KPTI) for the commercialization of XPOVIO® (selinexor), an FDA-approved cancer medicine for adults with Multiple Myeloma and Lymphoma. “We are thrilled to launch on the heels of our first licensing agreement to deliver a novel cancer treatment for Canadians,” said Kevin Leshuk, Founder and President of FORUS.

Read full press release